Programme
Preliminary programme:
| REGISTRATION | |
| 09:30 – 10:00 | Coffee and registration |
| OPENING & WELCOME | |
| 10:00 – 10:10 | Welcome |
| Prof. Sybe Schaap | |
| SESSION 1: | PLENARY SESSION - NOVEL DEVELOPMENTS |
| 10:15-11:00 | Opportunities and Challenges for RNA vaccines and therapeutics. |
| Prof. Robin Shattock - Department of Infectious Disease, Imperial College London | |
| 11:00-11:45 | Opportunities and Challenges for virus-based therapeutics in humans. |
| Prof. Ron Fouchier - Department of Viroscience, Erasmus Medical Center | |
| 11:45 – 13:15 | Lunch |
| SESSION 2: | CLINICAL AND VETERINARY THERAPEUTICS |
| 13:15- 13:45 | First-in-human clinical trial with an alphavirus-based replicon vaccine against HPV-induced cancers. |
| Prof. Toos Daemen - Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen | |
| 13:45 - 14:15 | Vaccine platform technologies within Animal Health - Possibilities and limitations. |
| Dr. Martijn Langereis - MSD Animal Health | |
| SESSION 3: | BIOSAFETY ASPECTS (working title) |
| 14:15 - 14:45 |
Viral replicon systems and their biosafety aspects. |
| Dr. Karen van der Meulen - Perseus | |
| 14:45 - 15:15 | Rise of the RNA machines - self-amplification as next step in mRNA vaccine design. |
| Dr. Gorben Pijlman - Laboratory of Virology, Wageningen University | |
| 15:15– 15:45 | Coffee Break |
| SESSION 4: | CONSIDERATIONS FOR REGULATION |
| 15:45 - 16:05 | Title tba. |
| Dr. Marco Gielkens - GMO office, National Institute for Public Health and the Environment | |
| 16:05 - 17:15 | Other speakers tba. Session includes discussion on future proof regulation |
| CONCLUDING REMARKS | |
| 17:15 - 17:25 | Concluding remarks |